SEC Form 4 · accession 0001140361-17-007883
BioRestorative Therapies, Inc. · BRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles S. Ryan
Director
Period of report
Feb 14, 2017
Accepted (ET)
Feb 16, 2017 · 1:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001505497
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 16,250 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionF4,F1 | $8.00 | Feb 14, 2017 | D | 15,000 | D | — | Apr 6, 2025 | Common Stock | 15,000 | 0 | D |
| OptionF4,F1 | $4.70 | Feb 14, 2017 | A | 15,000 | A | — | Apr 6, 2025 | Common Stock | 15,000 | 15,000 | D |
| OptionF4,F2 | $7.00 | Feb 14, 2017 | D | 20,000 | D | — | Sep 4, 2025 | Common Stock | 20,000 | 0 | D |
| OptionF4,F2 | $4.70 | Feb 14, 2017 | A | 20,000 | A | — | Sep 4, 2025 | Common Stock | 20,000 | 20,000 | D |
| Warrant | $15.00 | holding | — | — | — | May 8, 2015 | May 8, 2020 | Common Stock | 2,500 | 2,500 | D |
| Warrant | $4.00 | holding | — | — | — | Dec 7, 2015 | Nov 12, 2020 | Common Stock | 6,250 | 6,250 | D |
| OptionF3 | $3.73 | holding | — | — | — | — | Jun 10, 2026 | Common Stock | 46,000 | 46,000 | D |
Explanation of responses
- F1The option vests to the extent of 5,000 shares on each of April 6, 2016, April 6, 2017 and April 6, 2018.
- F2The option is exercisable to the extent of 10,000 shares on December 22, 2015, 3,334 shares on September 4, 2016, and 3,333 shares on each of September 4, 2017 and September 4, 2018.
- F3The option is exercisable to the extent of 15,334 shares on June 10, 2016 and 15,333 shares on each of June 10, 2017 and June 10, 2018.
- F4The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price.